skip to main content
Show Results with:

Drug Treatment of Idiopathic Pulmonary Fibrosis

Canestaro, William J. et al.

Chest. Volume 149:Issue 3 (2016); pp 756-766 -- Elsevier

Online access

  • Title:
    Drug Treatment of Idiopathic Pulmonary Fibrosis
  • Author: Canestaro, William J.;
    Forrester, Sara H.;
    Raghu, Ganesh;
    Ho, Lawrence;
    Devine, Beth E.
  • Found In: Chest. Volume 149:Issue 3 (2016); pp 756-766
  • Journal Title: Chest
  • Subjects: IPF--%FVC--SUCRA; epidemiology (pulmonary)--evidence-based medicine--idiopathic pulmonary fibrosis--meta-analysis; Dewey: 616.2
  • Rights: Licensed
  • Publication Details: Elsevier
  • Abstract: Background Idiopathic pulmonary fibrosis (IPF) is a form of chronic progressive fibrosing interstitial lung disease of unknown origin. Recently, nintedanib and pirfenidone demonstrated efficacy in slowing disease progression and were approved by the US Food and Drug Administration. Although numerous treatments have been evaluated in IPF, none have shown significant decreases in mortality. The objective of this study was to identify all pharmacologic treatments evaluated for IPF and analyze their efficacy via Bayesian network meta-analysis and pairwise indirect treatment comparisons. This review did not evaluate the effect of steroid therapy. Methods We searched MEDLINE, Embase, and the Cochrane Library for studies published on or before August 2014. Studies were required to contain a randomized evaluation of nonsteroidal drug therapy for treatment of IPF and be published in English. Key outcomes of interest for this analysis were pulmonary function as measured by FVC as well as all-cause and respiratory-specific death. All outcomes were analyzed via a Bayesian framework. Results Our review identified 30 eligible studies that evaluated 16 unique treatments. Under both the fixed-effect and random-effect models for respiratory-specific mortality, no treatments performed better than placebo. For all-cause mortality, pirfenidone and nintedanib had effects approaching significance with credible intervals slightly crossing the null under a fixed-effect model. Notably, for respiratory-specific mortality, all-cause mortality, and decline in percent predicted FVC, nintedanib and pirfenidone were virtually indistinguishable and no clear advantage was detected. Conclusions Although two treatments have been approved for IPF on the basis of reduced decline in pulmonary function, neither one has a clear advantage on mortality outcomes.
  • Identifier: System Number: ETOCvdc_100052207299.0x000001; Journal ISSN: 0012-3692; 10.1016/j.chest.2015.11.013
  • Publication Date: 2016
  • Physical Description: Electronic
  • Shelfmark(s): 3172.530000
  • UIN: ETOCvdc_100052207299.0x000001

Searching Remote Databases, Please Wait